abcellera.comHome -

AbCelleraTeam Partners Science Pipeline Platforms Engine Resources News & Events Investors Contact Careers We are Breaking barriers to develop better antibody medicines for patients.Play Pause We partner with Regeneron Lilly Moderna Gilead Novartis Abdera Denali Incyte IGM Teva Regeneron Lilly Moderna Gilead Novartis Abdera Denali Incyte IGM Teva Regeneron Lilly Moderna Gilead Novartis Abdera Denali Incyte IGM Teva Regeneron Lilly Moderna Gilead Novartis Abdera Denali Incyte IGM Teva We are developing potential first-in-class and best-in-class antibody medicines. We are focused on bringing innovative medicines to patients, both by advancing our internal pipeline of programs and partnering with companies that have novel science or innovative technology. We have developed antibody discovery and development technologies to unlock high-value drug classes and targets, including T-cell engagers for cancer and transmembrane proteins for indications such as metabolic and endocrine conditions, pain, autoimmunity, and more. Case Study Designing T-cell engagers to widen the therapeutic window T-cell engagers (TCEs) are among the most promising new modalities in cancer therapy, but limitations in efficacy and safety have been barriers to realizing their potential for solid tumor indications. Data shown here illustrate that we can repeatedly generate TCEs that show potent tumor-cell killing without excessive cytokine release in vitro across multiple tumor targets. View our scientific case studies Case Study Functional and specific T-cell engagers for a peptide-MHC tumor target Case Study Discovery of diverse GPCR-targeted antibodies View our scientific case studies People connected in purpose. We are a team of scientists, engineers, creatives, and business professionals who believe that advancing science enhances lives. And it all starts with our team. We’ve built a place where people feel they are part of something bigger than themselves. A place that exists to push the limits of science and technology, and aims to bring better therapies to patients.When I joined AbCellera, my first impression was they trust me”. There’s recognition that we all bring something unique to the table. That helps us bring our best selves to tackle the big problems every day. Robert Flemmer, Logistics Manager When I saw a Canadian company tackling such globally impactful problems, I immediately wanted to join the team. Everyone I work with is engaged, interested, and passionate about the work we are doing! Jessica Patterson, Senior Manager, Corporate Development Our family relocated to Vancouver from Boston — it’s a great place to raise our kids. We’re big hikers, bikers, and skiers, and take every chance we get to drive 25 min to the mountains and go on an adventure! Allie Goodman, Senior Research Scientist, Translational I wanted to keep doing work that could directly impact patient health. AbCellera allows me to do that, all while working with an incredibly collaborative team who do what it takes to get the job done together. Grace Leung, Principal Scientist AbCellera’s commitment to people, teams, and relationships is what drew me towards the company. I’m surrounded by brilliant, kind, and down-to-earth people every day, and I’m excited to contribute to this team. Tiffany Mintah, Learning and Development Program Manager Meet our team Events Connect with us. Meet with our team to discuss how we can expand the reach of antibody therapies. Apr 15 – 17, 2024 PEGS 2024 Boston, MA Apr 15 – 17, 2024 Festival of Biologics 2024 San Diego, CA Apr 5 – 10, 2024 AACR Annual Meeting San Diego, CA Jan 8 – 11, 2024 JPM Annual Healthcare Meeting 2024 San Francisco, CA Dec 13 – 16, 2023 Antibody Engineering & Therapeutics USA San Diego, CA Nov 16, 2023 Drug Discovery World Cancer Research Summit Virtual Nov 14, 2023 AbCellera R&D Day at MassBio MassBioHub, 700 Technology Square, 5th Floor, Cambridge, MA 02139 Nov 13 – 16, 2023 PEGS Europe Lisbon, Portugal Nov 1 – 5, 2023 SITC Annual Meeting San Diego, CA Apr 15 – 17, 2024 PEGS 2024 Boston, MA AbCellera will be presenting at PEGS on May 14, 2024 at 4:30PM ET. Apr 15 – 17, 2024 Festival of Biologics 2024 San Diego, CA AbCellera will be presenting on April 16 at 6:10pm PDT at Festival of Biologics 2024. Apr 5 – 10, 2024 AACR Annual Meeting San Diego, CA AbCellera will be presenting four posters at AACR 2024: Functional and specific T-cell engagers against a peptide-MHC tumor target ( Abstract #2373 ) Diverse CD28-binding IgG and heavy chain-only antibodies for T-cell engager development ( Abstract #1859 ) Target-dependent considerations for the design of bispecific T-cell engagers ( Abstract #1868 ) Development of PSMA x CD3 T-cell engagers using an integrated, functional approach ( Abstract #6359 ) See the press release Jan 8 – 11, 2024 JPM Annual Healthcare Meeting 2024 San Francisco, CA AbCellera will be at the JPM Annual Healthcare Meeting 2024. Join our company presentation on January 12 at 2:15pm PST to learn how AbCellera is bringing innovative medicines to patients, both by advancing our internal pipeline of programs and partnering with companies that have novel science or innovative technology. Dec 13 – 16, 2023 Antibody Engineering & Therapeutics USA San Diego, CA AbCellera will be presenting at Antibody Engineering & Therapeutics USA in San Diego, California. Nov 16, 2023 Drug Discovery World Cancer Research Summit Virtual Raffi Tonikian, AbCellera’s Director of Translational Biomarkers, will be presenting the talk Early integration of biomarker-driven approaches for bispecific development” at DDW’s Cancer Research Summit. Nov 14, 2023 AbCellera R&D Day at MassBio MassBioHub, 700 Technology Square, 5th Floor, Cambridge, MA 02139 AbCellera is hosting an R&D Day at MassBio. Join our talk on antibody development against previously intractable targets with Bo Barnhart, Vice President of Translational Research at AbCellera. Attendees can apply themes of how to succeed with more challenging programs to their own pipeline. See the agenda and register here . Nov 13 – 16, 2023 PEGS Europe Lisbon, Portugal AbCellera will be presenting at PEGS Europe in Lisbon, Portugal: Talk – Selecting optimal antibodies for IND-enabling studies with an integrated high-throughput & lead assessment platform Posters – Antibody candidates ready for IND-enabling studies with an integrated antibody discovery and development engine – Targeting intracellular tumor antigens to fight cancer: Discovery and development of functional and specific T-cell engagers against a MAGE-A4 pMHC Nov 1 – 5, 2023 SITC Annual Meeting San Diego, CA AbCellera will be presenting two posters at SITC 2023: – A rational approach for selecting CD3-binding antibodies for T-cell engager development (Abstract #1367) – Targeting intracellular tumor antigens to fight cancer: Discovery and development of functional and specific T-cell engagers against a MAGE-A4 pMHC (Abstract # 1395) In the News May 7, 2024 AbCellera Reports Q1 2024 Business Results Read article May 1, 2024 AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies Read article April 8, 2024 AbCellera presents data on T-cell engagers against four tumor targets at AACR 2024 Read article Read more Let’s talk Innovation. TeamOur team Partners Partner with us Platform GPCRs & ion channels T-cell engagers Peptide-MHCs Science Our pipeline Our platforms Our engine Resources Scientific case studies Presentations & posters Publications News & Events In the news Press kit Careers Work with us Current openings Contact Us AbCellera 2215 Yukon Street Vancouver, BC V5Y 0A1 office: 604.559.9005 Legal...